Metabolic syndrome, hyperinsulinemia, and colon cancer: A review

American Journal of Clinical Nutrition

Volumn 86, Issue 3, 2007, Pages

  Giovannucci, Edward ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colon cancer; Epidemiology; Exercise; Insulin; Metabolic syndrome; Obesity

Indexed keywords

INSULIN; SOMATOMEDIN C;

ADENOMA; BLOOD; BODY MASS; COLON TUMOR; EXERCISE; HUMAN; HYPERINSULINISM; HYPERTENSION; LIFESTYLE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ADENOMA; BODY MASS INDEX; COLONIC NEOPLASMS; EXERCISE; HUMANS; HYPERINSULINISM; HYPERTENSION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIFE STYLE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 40349105880     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.1093/ajcn/86.3.836s     Document Type: Conference Paper

References (65)

1. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
2. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003;108:1546-51. (Pubitemid 37187778)
3. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164-79.
4. Gerber M, Corpet D. Energy balance and cancers. Eur J Cancer Prev 1999;8:77-89. (Pubitemid 29210213)
5. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:687-95. (Pubitemid 24377963)
6. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996;7:605-25. (Pubitemid 26377730)
7. Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 2001;10:287-301. (Pubitemid 32703212)
8. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S. (Pubitemid 33070788)
9. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:920-31. (Pubitemid 44018922)
10. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54. (Pubitemid 29330553)
11. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
12. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control 1994;5:38-52. (Pubitemid 24066592)
13. Martinez ME, Giovannucci E, Spiegelman D, et al. Physical activity, body size, and colorectal cancer in women. Am J Epidemiol 1996;143: S73(abstr).
14. Russo A, Franceschi S, La Vecchia C, et al. Body size and colorectal cancer risk. Int J Cancer 1998;78:161-5. (Pubitemid 28443171)
15. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 1996;7:253-63. (Pubitemid 26155463)
16. Shinchi K, Kono S, Honjo S, et al. Obesity and adenomatous polyps of the sigmoid colon. Jpn J Cancer Res 1994;85:479-84. (Pubitemid 24164634)
17. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005;11:3642-6. (Pubitemid 40685579)
18. Sass DA, Schoen RE, Weissfeld JL, et al. Relationship of visceral adipose tissue to recurrence of adenomatous polyps. Am J Gastroenterol 2004;99:687-93. (Pubitemid 38612816)
19. Almendingen K, Hofstad B, Vatn MH. Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol 2001;96:2238-46. (Pubitemid 32660924)
20. La Vecchia C, D'Avanzo B, Negri E, Franceschi S. History of selected diseases and the risk of colorectal cancer. Eur J Cancer 1991;27:582-6.
21. Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu L-C. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997;57:4787-94. (Pubitemid 27468985)
22. Kono S, Honjo S, Todoroki I, et al. Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). Cancer Causes Control 1998;9:441-6. (Pubitemid 28466697)
23. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998;147:816-25. (Pubitemid 28244386)
24. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542-7. (Pubitemid 29157063)
25. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12: 412-8. (Pubitemid 36578478)
26. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87. (Pubitemid 41672234)
27. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst 2006;98:135-8. (Pubitemid 43159968)
28. Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol 2006; 101:1866-71. (Pubitemid 44166599)
29. Meigs JB, D'Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: The Framingham Offspring Study. Diabetes 1997;46:1594-600. (Pubitemid 27411235)
30. Hanley AJ, Karter AJ, Festa A, et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study [Complications]. Diabetes 2002;51:2642-7. (Pubitemid 34827418)
31. Strazullo P, Barba G, Cappuccio FP, et al. Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens 2001;19:2157-64. (Pubitemid 33135236)
32. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36. (Pubitemid 43941640)
33. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002;11:385-91. (Pubitemid 34408218)
34. Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006; 164:652-4.
35. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol 2005;20:1410-5. (Pubitemid 43960840)
36. Topping DL, Mayes PA. The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism. Biochem J 1972;126:295-311.
37. Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. Metabolism 1981;30:165-71. (Pubitemid 11154399)
38. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102:179-84. (Pubitemid 30451774)
39. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Risk Factors and Life Expectancy Research Group. Cancer Epidemiol Biomarkers Prev 2001; 10:937-41. (Pubitemid 32844900)
40. Tsushima M, Nomura AM, Lee J, Stemmermann GN. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 2005;50:499-505. (Pubitemid 40543738)
41. Yamada K, Araki S, Tamura M, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998;27:794-8. (Pubitemid 28504966)
42. Bayerdorffer E, Mannes GA, Richter WO, et al. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med 1993;118:481-7. (Pubitemid 23085789)
43. Park SK, Joo JS, Kim DH, Kim YE, Kang D, Yoo KY. Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: a case-control study in Korea. J Korean Med Sci 2000;15:690-5.
44. Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol 2006;12:1261-4.
45. Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW. Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomarkers Prev 1996;5:607-12. (Pubitemid 26265154)
46. Manus B, Adang RP, Ambergen AW, Bragelmann R, Armbrecht U, Stockbrugger RW. The risk factor profile of recto-sigmoid adenomas: a prospective screening study of 665 patients in a clinical rehabilitation centre. Eur J Cancer Prev 1997;6:38-43. (Pubitemid 27239516)
47. Misciagna G, De Michele G, Guerra V, Cisternino AM, Di Leo A, Freudenheim JL. Serum fructosamine and colorectal adenomas. Eur J Epidemiol 2004;19:425-32. (Pubitemid 39012755)
48. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001;84:417-22. (Pubitemid 32154439)
49. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003;157:1092-100. (Pubitemid 36682301)
50. Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E. Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 1999;10:379-86. (Pubitemid 29454314)
51. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res 2002;93:1187-94. (Pubitemid 36032980)
52. Nishii T, Kono S, Abe H, et al. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese men. Jpn J Cancer Res 2001; 92:836-40. (Pubitemid 32894092)
53. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2006;15: 750-5.
54. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2076-81. (Pubitemid 41603248)
55. Chiu HM, Lin JT, Shun CT, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007;5:221-9.
56. Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces Health Study. Asian Pac J Cancer Prev 2005;6:485-9.
57. Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 1984;19:297-352.
58. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
59. Palmqvist R, Stattin P, Rinaldi S, et al. Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in Northern Sweden. Int J Cancer 2003;107:89-93. (Pubitemid 37100090)
60. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004; 96:546-53. (Pubitemid 38559579)
61. Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5. (Pubitemid 40478547)
62. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
63. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127:1044-50. (Pubitemid 39345873)
64. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-64.
65. Tran TT, Naigamwalla D, Oprescu AI, et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 2006;147:1830-7.